Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $14
Bicycle Therapeutics Limited
Bicycle Therapeutics Limited BCYC | 0.00 |
Needham analyst Ami Fadia maintains Bicycle Therapeutics (NASDAQ:
BCYC) with a Buy and lowers the price target from $15 to $14.
